此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

大脑中胰岛素异常作用是否是精神分裂症患者认知和代谢功能障碍的基础

2026年9月24日 更新者:Centre for Addiction and Mental Health

Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes. Additionally, almost half of the patients with SCZ are obese, the prevalence of type 2 diabetes is 3-6 times higher, and life expectancy is lower by 15-20 years compared to the general population. This is relevant as metabolic syndrome and diabetes are both associated with worse cognition among SCZ patients. Recent work studying the relationships between metabolic health and cognition has encouraged a new way of thinking about SCZ as both a metabolic and cognitive disorder. Brain insulin is involved in several processes relevant to SCZ, and abnormal brain insulin action may help explain both cognitive and metabolic abnormalities in patients with SCZ, but this has not been examined previously. Glucose uptake in several brain regions relevant to SCZ has been shown to be partially dependent on insulin. Therefore, in this study, the researchers will measure glucose uptake in the brain using an 18F-fluorodeoxyglucose ([18F]-FDG) positron emission tomography (PET) scan after an intranasal insulin stimulus, and will compare this measure between patients with SCZ and healthy controls.

研究概览

地位

主动,不招人

详细说明

i) Schizophrenia and cognition: Cognitive impairment is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes. Antipsychotics reduce positive symptoms but there are no currently approved treatments for cognitive impairment, creating a large unmet need.

ii) Schizophrenia and metabolic dysfunction: Patients with SCZ also have exceedingly high rates of metabolic comorbidity. Almost half of patients are obese and the prevalence of type 2 diabetes is 3-9 fold higher than the general population. Patients with SCZ die on average 15-20 years earlier than the general population from cardiovascular disease. Thus, metabolic health represents another large unmet need.

iii) Association between cognitive and metabolic dysfunction: These two domains of dysfunction interact in an additive manner to worsen outcomes. Metabolic syndrome and diabetes are both associated with worse cognition among SCZ patients. Recent knowledge elucidating the interactions between metabolic health, cognition, and functioning have encouraged a reconceptualization of SCZ as both a metabolic and cognitive disorder, prompting search for treatment strategies that address abnormalities in both these aspects.

iv) Brain insulin as a unifying link: There has been recent recognition that insulin plays an important role in the brain. Brain insulin is implicated in several processes relevant to SCZ. Abnormal brain insulin action may help explain both cognitive and metabolic aberrations in patients with SCZ. Moreover, it is now clear that glucose uptake in the brain is partially dependent on insulin in brain regions relevant to SCZ, such as the hippocampus, hypothalamus, and striatum.

v) Evidence and promise in SCZ: There is preliminary evidence to suggest that brain insulin resistance is associated with worse cognition. A magnetic resonance spectroscopy (1H-MRS) study found higher brain glucose and lower glucose utilization in SCZ patients, suggesting brain insulin resistance, that were associated with memory impairment. Initial intervention studies using intranasal insulin have not been successful, likely because resistance to insulin in the brain prevents any benefits of intranasal insulin from accruing. However, this has not been conclusively demonstrated. This study seeks to answer this question directly.

vi) Role of 18-fluorodeoxyglucose ([18F]-FDG)-positron emission tomography (PET): 1H-MRS is an indirect and imprecise measure of glucose in the brain (it combines intra- and extracellular glucose). This is also true for other MRI based measures, which have recently been employed to indirectly study insulin action in the brain. Currently, there are no PET ligands able to reliably quantify insulin or its receptors in the brain. However, using [18F]-FDG PET, it is possible to measure differences in glucose uptake, with and without an insulin challenge, into insulin sensitive regions of the brain (e.g. hippocampus and striatum). This can serve as a surrogate marker of brain insulin action. This principle has already been used successfully in rodents and healthy humans, and offers a more direct method of quantifying brain insulin action.

In this study, [18F]-FDG PET will be employed to examine whether abnormal brain insulin action is a feature of SCZ. The study examines young SCZ patients. Insulin (160 IU; shown to be safe and effective previously) will be delivered intranasally as it has been shown to be reliable method of delivering insulin to the brain.

Primary hypothesis: SCZ patients will have reduced [18F]-FDG uptake, in response to an intranasal insulin challenge, compared to healthy controls.

研究类型

介入性

注册 (估计的)

20

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Ontario
      • Toronto、Ontario、加拿大、M6J1H3
        • Centre for Addiction and Mental Health

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

17年 至 45年 (孩子、成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

i) Experimental group (participants with a diagnosis of schizophrenia spectrum disorder):

  1. 17-45 years
  2. both sexes;
  3. Patients with first-episode schizophrenia spectrum illness: Primary DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, psychotic disorder NOS, major depressive disorder with psychotic symptoms, bipolar I disorder, and bipolar II disorder, OR substance-induced psychosis, and antipsychotic treatment for schizophrenia, schizoaffective disorder, or other specified schizophrenia spectrum, other psychotic disorder, major depressive disorder with psychotic symptoms, bipolar I disorder, and bipolar II. (Diagnosis willbe confirmed via CAMH chart review).
  4. BMI under or equal to 27

ii) Control group (healthy controls):

  1. 17-45 years of age
  2. sex-,
  3. hand dominance -and
  4. body mass index (BMI)-matched
  5. Absence of DSM-5 diagnosis other than a specific phobia according to MINI

Exclusion Criteria:

  1. moderate or severe substance use according to MINI (per PI discretion in the case of moderate alcohol or cannabis use)
  2. prediabetes, diabetes, or evidence of impaired glucose tolerance on screening OGTT
  3. acute suicidal risk
  4. use of weight, lipid, antidiabetic or blood pressure reducing agents
  5. liver or kidney disease
  6. pregnancy
  7. nursing
  8. pacemakers
  9. metallic cardiac valves
  10. magnetic material such as surgical clips, implanted electronic infusion pumps or any other conditions that would preclude the MRI scan
  11. clinically significant claustrophobia (determined from MRI screening form; significance evaluated as per QI's discretion).
  12. history of head trauma resulting in loss of consciousness > 30 minutes that required medical attention;
  13. size of head, neck, precluding to fit in the MRI or PET scanners
  14. weight over 350lbs (limit for MRI scanner bed)
  15. unstable physical illness
  16. significant neurological disorder including a seizure disorder;
  17. Received maximum allowed radiation in the past 12 months (20 mSv)
  18. Completed more than 6 PET scans/ lifetime, that, together with the PET scanning procedures under this protocol will bring the total number of PET scans to more than the allowed/lifetime (8 PET scans per lifetime). These limits are set by the Centre for Addiction and Mental Health Brain Health Imaging Centre Guideline.
  19. clinically relevant abnormality observed in medical history,
  20. current intake of any medication that may interfere with participation in the study or may confound the results of PET imaging (e.g. anti-diabetic medication).
  21. Disorders of coagulation, blood or ongoing use of anticoagulant medication

Control group: Exclusionary criteria are as listed above for participants, in addition to:

1) First degree family member with primary psychotic disorder.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Schizophrenia Group

Insulin (160IU) or placebo is administered intranasally 15 minutes prior to the PET scan.

160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

其他名称:
  • 优泌乐

0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

其他名称:
  • 盐水
实验性的:Healthy Control Group

Insulin (160 IU) or placebo is administered intranasally 15 minutes prior to the PET scan.

160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

其他名称:
  • 优泌乐

0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

其他名称:
  • 盐水

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
[18F]-FDG brain uptake
大体时间:Scan duration is ~90 minutes

Change in [18F]-FDG uptake in striatum and hippocampus is measured in response to intranasal insulin challenge or placebo

Scan duration is ~90 minutes

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年4月1日

初级完成 (估计的)

2026年12月31日

研究完成 (估计的)

2026年12月31日

研究注册日期

首次提交

2023年2月18日

首先提交符合 QC 标准的

2023年2月28日

首次发布 (实际的)

2023年3月1日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅